An increase in intensive care unit (ICU) management and bacterial pneumonia development occurs in children with special risk medical conditions (SRMC), but a rise in the probability of death or need for mechanical ventilation remains inconsistent, suggests a recent study.
The severity criteria of the British Thoracic Society (BTS) guideline for paediatric community-acquired pneumonia (CAP) boast of a fair to excellent capacity in predicting the need for hospitalization (NFH) and disposition, a study has shown.
The 30-day all-cause mortality is similar between definitive therapy with vancomycin or a beta-lactam among patients with an ampicillin-susceptible enterococcal bloodstream infection (BSI), a recent study has shown.
Monthly supplementation with high-dose vitamin D does little to stave off the risk of developing acute respiratory infection in older adults with low prevalence of profound vitamin D deficiency, a study has found.
Women who develop infection during delivery hospitalization are at higher risk of being readmitted for ischaemic stroke within 30 days postpartum, especially those with no hypertensive disorders of pregnancy, a study reports.
A third of Clostridium difficile infection (CDI) patients with cirrhosis have been readmitted in a span of 30 days primarily due to recurrent CDI, a recent study has found. In addition, there is a high rate of mortality linked to CDI in patients with cirrhosis, in which a poor prognosis is predicted by decompensation and 30-day readmission.
The high-dose influenza vaccine confers no additional protection beyond the standard-dose vaccine (SDV) in terms of all-cause mortality or influenza-related outcomes in adults undergoing maintenance haemodialysis, as shown in a recent study.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.